Sonic Incytes Named 2026 MedTech Emerging Company of the Year
Sonic Incytes has been recognized by Life Sciences BC as the 2026 Emerging Company of the Year – MedTech. The award recognizes companies making significant contributions to British Columbia’s life sciences community through growth, innovation, and impact. Life Sciences BC presents the awards each year. They recognize individuals and companies helping advance healthcare through science […]
FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases
VANCOUVER, British Columbia–(BUSINESS WIRE)–Sonic Incytes Medical Corp, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE™, its point-of-care ultrasound elastography device. Building on the success of its original model, Velacur™, Velacur ONE™ introduces an enhanced interface and features for improved portability and user experience. These improvements enable […]
FDA Grants 510(k) Clearance to Sonic Incytes’ Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH
VANCOUVER, British Columbia — (BUSINESS WIRE) — Sonic Incytes Medical Corp, a leader in point-of-care ultrasound, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Velacur® Determined Fat Fraction (VDFF). This innovative measurement tool is integrated into the Velacur® device software, combining quantitative measures of ultrasound attenuation and […]
Sonic Incytes to Present Data at EASL International Liver Congress™️ 2023
Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification We are excited to announce that clinical data from Sonic Incytes’ multi-center study will be presented at the prestigious European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 in Vienna, Austria. The poster presentation highlights the comparison between point-of-care liver quantification tools, […]
Sonic Incytes Receives FDA 510(k) Clearance of AI Powered Features for Velacur™️ Liver Ultrasound
Sonic Incytes is pleased to announce they have received Food and Drug Administration (FDA) clearance for new Organ Guide and Wave Quality Detector features for Velacur™️, the Company’s liver diagnostic tool. These new artificial intelligence and machine learning (AI-ML)-based tools will improve the accuracy and performance of the device and enable less experienced medical personnel […]
Sonic Incytes Announces Clinical Trial Data Comparing Velacur™️ and FibroScan®
Sonic Incytes Medical Corp. is pleased to announce clinical data from a prospective multi-center study comparing the effectiveness of Velacur™️ and FibroScan® in measuring liver fibrosis and fat in patients with suspected NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). The results confirmed earlier findings that Velacur can effectively differentiate between various stages of […]
Sonic Incytes Announces Velacur™️ use in Madrigal Pharmaceuticals’ Open-Label Extension Clinical Trial
Sonic Incytes Medical Corp. is pleased to announce the inclusion of Velacur™️ — the first handheld 3D liver health assessment tool—in a subset of Madrigal Pharmaceutical’s MAESTRO NAFLD-1 Phase 3 Open Label Extension study of resmetirom (MGL-3196-18). As part of this Madrigal study, a subset of patients will undergo VelacurTM imaging at baseline (Day 1), Week […]
Sonic Incytes Receives Award at 2022 Digestive Disease Week Conference
The poster entitled “Accuracy of Velacur™️ AI Powered Liver Guide in Identification of Liver” presented at the Digestive Disease Week (DDW) Conference in San Diego, California received a Poster of Distinction Award. The poster reported on results from a multi-center study carried out to assess the performance of a new AI powered liver guide being […]
Sonic Incytes Appoints New CEO and Chair to Accelerate Growth
Following the closing of its US$7.3M Series A raise in December 2021, the Sonic Incytes Medical Corp. Board of Directors is pleased to announce the appointment of Barry Allen as the new CEO and Natalie Dakers as the new Board Chair to lead the company through its next stage of growth. “Our focus is on […]
Sonic Incytes Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization
Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors. […]
